Last reviewed · How we verify

BOTOX-A

Baylor College of Medicine · FDA-approved active Small molecule Quality 6/100

BOTOX-A is a Small molecule drug developed by Baylor College of Medicine. It is currently FDA-approved. Also known as: BTX-A, Botulinum Toxin Type A, Generic Name: Botulinum toxin type A.

At a glance

Generic nameBOTOX-A
Also known asBTX-A, Botulinum Toxin Type A, Generic Name: Botulinum toxin type A
SponsorBaylor College of Medicine
ModalitySmall molecule
Therapeutic areaNeuroscience
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about BOTOX-A

What is BOTOX-A?

BOTOX-A is a Small molecule drug developed by Baylor College of Medicine.

Who makes BOTOX-A?

BOTOX-A is developed and marketed by Baylor College of Medicine (see full Baylor College of Medicine pipeline at /company/baylor-college-of-medicine).

Is BOTOX-A also known as anything else?

BOTOX-A is also known as BTX-A, Botulinum Toxin Type A, Generic Name: Botulinum toxin type A.

What development phase is BOTOX-A in?

BOTOX-A is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing